Literature DB >> 1316431

Treatment of Alzheimer's disease.

D M Bowen, P T Francis, A W Procter, A B Young.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1316431      PMCID： PMC489052          DOI： 10.1136/jnnp.55.4.328

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  21 in total

1.  Cortical nicotinic receptors in Alzheimer's disease and Parkinson's disease.

Authors:  K W Lange; F R Wells; M N Rossor; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

2.  A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease.

Authors:  M M Esiri; R C Pearson; J E Steele; D M Bowen; T P Powell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

3.  Synaptic targets of HRP-filled layer III pyramidal cells in the cat striate cortex.

Authors:  Z F Kisvárday; K A Martin; T F Freund; Z Maglóczky; D Whitteridge; P Somogyi
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

4.  Nerve growth factor potentiates the neurotoxicity of beta amyloid.

Authors:  B A Yankner; A Caceres; L K Duffy
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

Authors:  G B Watson; M A Bolanowski; M P Baganoff; C L Deppeler; T H Lanthorn
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

6.  Characterisation of the glycine modulatory site of the N-methyl-D-aspartate receptor-ionophore complex in human brain.

Authors:  A W Procter; G C Stratmann; P T Francis; S L Lowe; P H Bertolucci; D M Bowen
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

Review 7.  Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee.

Authors:  M Swash; D N Brooks; N E Day; C D Frith; R Levy; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

8.  D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain.

Authors:  I P Chessell; A W Procter; P T Francis; D M Bowen
Journal:  Brain Res       Date:  1991-11-29       Impact factor: 3.252

9.  Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease.

Authors:  N R Cutler; J V Haxby; R Duara; C L Grady; A D Kay; R M Kessler; M Sundaram; S I Rapoport
Journal:  Ann Neurol       Date:  1985-09       Impact factor: 10.422

Review 10.  Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy.

Authors:  D M Bowen
Journal:  Br J Psychiatry       Date:  1990-09       Impact factor: 9.319
View more
  1 in total

Review 1.  Glutamate: its role in learning, memory, and the aging brain.

Authors:  W J McEntee; T H Crook
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.